Nipah virus vaccine mRNA-1215 was investigated in this phase 1, open-label, dose-escalation study in healthy adults. The vaccine encodes a Malaysian strain of Nipah virus, specifically the chimeric F1 perfusion protein linked to glycoprotein G. The study found the vaccine to be safe and elicit a promising immune response targeting glycoprotein G. The results support further development of this vaccine candidate. The study was published in Nature Medicine online on March 12, 2026.